RTTNews | Jan 8, 2021 07:41AM EST

07:40 Friday, January 8, 2021 (RTTNews.com) - Neurocrine Biosciences, Inc. (NBIX) said, based on preliminary unaudited financial information, the company expects INGREZZA net product sales for the three months and full-year ended December 31, 2020 to be approximately $240 million and $993 million respectively. INGREZZA inventory adjusted net product sales for the fourth quarter were approximately $258 million. Full-year 2020 total INGREZZA prescriptions grew 32% to approximately 175,700.

The company said it plans to provide clinical data for key programs and expects to begin seven additional mid-to-late stage clinical studies in 2021 for neurological, endocrine and psychiatric disorders.

Read the original article on RTTNews ( https://www.rttnews.com/3158891/neurocrine-biosciences-preliminary-full-year-ingrezza-net-product-sales-up-32.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved